{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:13:26Z","timestamp":1793740406879,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejmech.2019.04.060","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T11:13:57Z","timestamp":1556018037000},"page":"216-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Multi-targeted ChEI-copper chelating molecules as neuroprotective agents"],"prefix":"10.1016","volume":"174","author":[{"given":"Simona","family":"Sestito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Chiellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbiao","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-6358","authenticated-orcid":false,"given":"Simona","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.04.060_bib1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Association","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejmech.2019.04.060_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejmech.2019.04.060_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","article-title":"Cholinesterase inhibitors used in the treatment of Alzheimer's disease","volume":"21","author":"Wilkinson","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejmech.2019.04.060_bib4","series-title":"Classics in Chemical Neuroscience: Memantine","author":"Alam","year":"2017"},{"key":"10.1016\/j.ejmech.2019.04.060_bib5","first-page":"239","volume":"vol. 52","author":"Owen","year":"2016"},{"key":"10.1016\/j.ejmech.2019.04.060_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejmech.2019.04.060_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopha.2018.06.147","article-title":"A\u00a0molecular approach in drug development for Alzheimer's disease","volume":"106","author":"Agatonovic-Kustrin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2019.04.060_bib8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bmcl.2014.12.084","article-title":"Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD","volume":"25","author":"Digiacomo","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.04.060_bib9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ejmech.2016.09.052","article-title":"Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease","volume":"125","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2017.10.006","article-title":"Nature-based molecules combined with rivastigmine: a symbiotic approach for the synthesis of new agents against Alzheimer's disease","volume":"141","author":"Nesi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"27","key":"10.1016\/j.ejmech.2019.04.060_bib11","first-page":"3062","article-title":"Oxidative stress, mitochondrial abnormalities and proteins deposition: multitarget approaches in Alzheimer's disease","volume":"17","author":"Nesi","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00005053-198309000-00005","article-title":"Aluminum and Alzheimer's disease","volume":"171","author":"Shore","year":"1983","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.ejmech.2019.04.060_bib13","series-title":"Biometals in Neurodegenerative Diseases","first-page":"19","article-title":"Copper in Alzheimer's disease","author":"Squitti","year":"2017"},{"key":"10.1016\/j.ejmech.2019.04.060_bib14","series-title":"Neurotoxicity of Metals","first-page":"303","article-title":"Neurotoxicity of zinc","author":"Morris","year":"2017"},{"key":"10.1016\/j.ejmech.2019.04.060_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fnagi.2018.00065","article-title":"The aging of iron man","volume":"10","author":"Ashraf","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2019.04.060_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.freeradbiomed.2012.10.558","article-title":"Metallostasis in Alzheimer's disease","volume":"62","author":"Ayton","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2019.04.060_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/ijms19010128","article-title":"Metal ion effects on A\u03b2 and tau aggregation","volume":"19","author":"Kim","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2019.04.060_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1471-4159.2004.02948.x","article-title":"Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3\u03b2 in SH-SY5Y neuroblastoma cells","volume":"92","author":"An","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib19","first-page":"2011","article-title":"GSK-3 in neurodegenerative diseases","author":"Lei","year":"2011","journal-title":"Int. J. Alzheimer's Dis."},{"key":"10.1016\/j.ejmech.2019.04.060_bib20","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMra1800219","article-title":"The role of deferiprone in iron chelation","volume":"379","author":"Hider","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.04.060_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/ijms18010116","article-title":"Hydroxypyridinone chelators: from iron scavenging to radiopharmaceuticals for PET imaging with Gallium-68","volume":"18","author":"Cusnir","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2019.04.060_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/00958970008024563","article-title":"Synthesis and spectroscopic studies of some new redox-active benzylamine complexes of copper(II) and esr studies of their oxidationreduction products","volume":"52","author":"Kasumov","year":"2000","journal-title":"J.\u00a0Coord. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib23","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/0022-1902(65)80244-5","article-title":"4-methyl-pyridine adducts of copper (II) \u03b2-diketone chelates","volume":"27","author":"Walker","year":"1965","journal-title":"J.\u00a0Inorg. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib24","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1039\/B916366B","article-title":"Two pyridine derivatives as potential Cu (II) and Zn (II) chelators in therapy for Alzheimer's disease","volume":"39","author":"Lakatos","year":"2010","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.060_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00205","article-title":"Multi-target directed donepezil-like ligands for Alzheimer's disease","volume":"10","author":"Unzeta","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2019.04.060_bib26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1212\/01.WNL.0000154531.79362.23","article-title":"Excess of serum copper not related to ceruloplasmin in Alzheimer disease","volume":"64","author":"Squitti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2019.04.060_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1212\/01.wnl.0000223343.82809.cf","article-title":"Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau","volume":"67","author":"Squitti","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2019.04.060_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000338568.28960.3f","article-title":"Longitudinal prognostic value of serum \"free\" copper in patients with Alzheimer disease","volume":"72","author":"Squitti","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2019.04.060_bib29","doi-asserted-by":"crossref","first-page":"20378","DOI":"10.1074\/jbc.M400805200","article-title":"Copper depletion down-regulates expression of the Alzheimer's disease amyloid-\u03b2 precursor protein gene","volume":"279","author":"Bellingham","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01247","article-title":"Advances in multi-functional ligands and the need for metal-related pharmacology for the management of Alzheimer disease","volume":"9","author":"Sharma","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.04.060_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1330","article-title":"Neurodegenerative diseases and oxidative stress","volume":"3","author":"Barnham","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.04.060_bib32","doi-asserted-by":"crossref","first-page":"7609","DOI":"10.1021\/bi990438f","article-title":"The A\u03b2 peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction","volume":"38","author":"Huang","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.04.060_bib33","doi-asserted-by":"crossref","first-page":"9270","DOI":"10.1021\/bi700508n","article-title":"Redox reactions of copper complexes formed with different beta-amyloid peptides and their neuropathological [correction of neuropathalogical] relevance","volume":"46","author":"Jiang","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.04.060_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2017.10.006","article-title":"Nature-based molecules combined with rivastigmine: a symbiotic approach for the synthesis of new agents against Alzheimer's disease","volume":"141","author":"Nesi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib35","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.4155\/fmc-2017-0094","article-title":"Advances toward multifunctional cholinesterase and \u03b2-amyloid aggregation inhibitors","volume":"9","author":"Panek","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib36","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1016\/j.bmcl.2012.08.036","article-title":"Design, synthesis and pharmacological evaluation of novel tacrine\u2013caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease","volume":"22","author":"Chao","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.04.060_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13311-014-0312-z","article-title":"Biometals and their therapeutic implications in Alzheimer's disease","volume":"12","author":"Ayton","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2019.04.060_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2019.04.060_bib39","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1039\/j19660001031","article-title":"Pyridine complexes of iron (II), copper (II), zinc (II), and cadmium (II) halides","author":"Allan","year":"1966","journal-title":"J.\u00a0Chem. Soc. A Inorg. Phys. Theor."},{"key":"10.1016\/j.ejmech.2019.04.060_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2478\/s11696-013-0528-0","article-title":"Synthesis, crystal structures, spectral, electrochemical and magnetic properties of di-\u03bc-phenoxido-bridged dinuclear copper (II) complexes with N-salicylidene-2-hydroxybenzylamine derivatives: axial coordination effect of dimethyl sulphoxide molecule","volume":"68","author":"Kakuta","year":"2014","journal-title":"Chem. Pap."},{"key":"10.1016\/j.ejmech.2019.04.060_bib41","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0022-1902(68)80289-1","article-title":"Complexes of 2-pyridone with MnCl2, CoCl2, NiCl2 and CuCl2","volume":"30","author":"Houk","year":"1968","journal-title":"J.\u00a0Inorg. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib42","article-title":"A\u00a0review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease","volume":"15","author":"Nordberg","year":"2013"},{"key":"10.1016\/j.ejmech.2019.04.060_bib43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejmech.2017.03.062","article-title":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease","volume":"132","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.060_bib44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3233\/JAD-140219","article-title":"Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?","volume":"42","author":"Macdonald","year":"2014","journal-title":"J.\u00a0Alzheimer's Dis."},{"key":"10.1016\/j.ejmech.2019.04.060_bib45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.ejmech.2019.04.060_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/14737175.2015.955853","article-title":"Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants","volume":"15","author":"Di Domenico","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2019.04.060_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00023210-200216050-00006","article-title":"The role of iron and copper in the aetiology of neurodegenerative disorders","volume":"16","author":"Perry","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2019.04.060_bib48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A\u00a0new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419303782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419303782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:54:17Z","timestamp":1759326857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419303782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":48,"alternative-id":["S0223523419303782"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.060","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-targeted ChEI-copper chelating molecules as neuroprotective agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}